Baumer Thomas, Higginbotham George, Hayes Kati, Thomas Matt
Specialist Registrar in Intensive Care Medicine, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Academic Foundation Doctor, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Neurotrauma Rep. 2024 Oct 2;5(1):982-987. doi: 10.1089/neur.2024.0055. eCollection 2024.
Following severe traumatic brain injury (TBI), elevated catecholamine levels are associated with worsened secondary brain injury and poorer clinical outcomes. The mechanisms are uncertain but may include cerebral ischemia and blood-brain barrier disruption, with consequent cerebral edema manifesting as intracranial hypertension. Early beta-blockade (EBB) may mitigate these detrimental hyperadrenergic effects. Therapy Intensity Level (TIL) is a validated score that quantifies intracranial pressure (ICP)-lowering interventions, with higher TIL being a surrogate for more severe intracranial hypertension. In this secondary analysis of a dose-finding study of EBB with esmolol in adults with TBI, we compared summary TIL (TIL24) and domain TIL between patients who received esmolol and those who did not. The primary outcome was TIL24 for each 24-h epoch of the esmolol intervention period of 96 h. Baseline characteristics were comparable in the esmolol (E) and non-esmolol (NE) groups. Mean TIL24 was similar in both groups up to 48 h but then diverged. The mean (standard deviation) TIL24 score between 48 and 72 h was 4.8 (1.5) in group E versus 6.6 (5.4) in group NE and at 72-96 h 4.5 (1.5) in group E versus 7.0 (4.0) in group NE. TIL domain scores were lower in group E for hyperosmolar therapy, targeted temperature management, and surgical management (cerebrospinal fluid drainage, evacuation, or decompressive craniectomy). The association between esmolol use after TBI and the reduction in ICP-directed interventions is consistent with an effect of beta-blockade on reduction of cerebral edema. Further research is necessary to determine causality and mechanism.
重度创伤性脑损伤(TBI)后,儿茶酚胺水平升高与继发性脑损伤加重及临床预后较差相关。其机制尚不确定,但可能包括脑缺血和血脑屏障破坏,随之出现的脑水肿表现为颅内高压。早期β受体阻滞剂治疗(EBB)可能减轻这些有害的高肾上腺素能效应。治疗强度水平(TIL)是一个经过验证的评分,用于量化降低颅内压(ICP)的干预措施,TIL越高代表颅内高压越严重。在这项对TBI成年患者使用艾司洛尔进行EBB剂量探索研究的二次分析中,我们比较了接受艾司洛尔治疗的患者与未接受治疗的患者之间的总TIL(TIL24)和各领域TIL。主要结局是艾司洛尔96小时干预期内每24小时时段的TIL24。艾司洛尔组(E)和非艾司洛尔组(NE)的基线特征具有可比性。两组在48小时内的平均TIL24相似,但之后出现差异。E组在48至72小时的平均(标准差)TIL24评分为4.8(1.5),而NE组为6.6(5.4);在72 - 96小时,E组为4.5(1.5),NE组为7.0(4.0)。在高渗治疗、目标温度管理和手术管理(脑脊液引流、清除或减压颅骨切除术)方面,E组的TIL领域评分较低。TBI后使用艾司洛尔与减少ICP导向干预之间的关联与β受体阻滞剂对减轻脑水肿的作用一致。有必要进行进一步研究以确定因果关系和机制。